%20(1))
Including pTau217, GFAP, NfL and Aβ 42/40
Across neurodegenerative diseases like Alzheimer's, Parkinson's and more
%20copy?fmt=webp-alpha)
From biomarker discovery to companion diagnostic commercialization
| Biomarker | Associated Diseases |
|---|---|
| NfL | Neurodegeneration: MS, ALS, AD, PD, FTD (frontotemporal dementia), HAND (HIV associated neurocognitive disorder), COVID-19 associated neurological disorders, concussion/mTBI |
| GFAP | Neurodegeneration: MS, AD, NMOSD (neuromyelitis optica spectrum disorder), COVID-19 associated neurological disorders, concussion/mTBI |
| pTau217 | AD |
| pTau181 | AD |
| Total tau | Tauopathies: AD, FTD with Parkinsons (PD), PSP (progressive supranuclear palsy), HAND, concussion/mTBI |
| Neuro 3-plex: Amyloid beta (1-42), Amyloid beta (1-40), total tau | AD, HAND |
| Neuro 4-plex E: Amyloid beta (1-42), Amyloid beta (1-40), NfL and GFAP | AD |
| Neuro 4-plex A: NfL, GFAP, Total Tau, UCH-L1 | Concussion/mTBI |
| a-synuclein | PD, AD |
| Amyloid beta (1-40) | AD |
| Amyloid beta (1-42) | AD |
| Amyloid beta 42/40 | AD |
| pTau231 | AD |
| Cytokine 3-plex: IL-6, TNFa, IL-10 | AD (inflammation) |
Check out our Alzheimer’s-specific biomarker offerings.
Leverage Labcorp’s deep knowledge supporting 90+ Alzheimer’s disease protocols–in 45+ countries with 96,000+ patients–in the last 5 years alone
?fmt=webp-alpha)
Access holistic and specialized neurology expertise for support from strategy to lab with our Biomarker Solution Center and global translational biomarker scientists
Experience Alzheimer's clinical trial testing delivered by a global laboratory network with critical sample management and logistics capabilities
